• Hormonal status of patients after surgical treatment of fibrocystic mastopathy and possibilityes of its corrections

Hormonal status of patients after surgical treatment of fibrocystic mastopathy and possibilityes of its corrections

HEALTH OF WOMAN. 2017.5(121):128–131; doi 10.15574/HW.2017.121.128

Pryshash Yu.Ya.
Lviv national medical University named Danylo Galitsky

The purpose of the study was to investigate the efficacy of Mastodynon in terms of indications in elevated doses versus the standard dose.

Materials and methods. Data were analyzed for 60 patients after surgical treatment of fibro-cystic mastopathy. Depending on the postoperative therapy received by the patients, they were divided into three groups. Group I (n = 20): patients were observed in accordance with the standards established in mammal practice and did not receive special agents that affect hormonal homeostasis. Group II (n = 20): In addition to observation, patients received Mastodynon® (1 tablet or 30 drops 2 times a day) for 6 months. Group III (n = 20): Patients were given for a post-operative rehabilitation Mastodynon® in a double dose (2 tablets or 60 drops 2 times a day) for 6 months.

Results Surgical treatment without conservative therapy  eliminates organic changes in the thoracic glands (GH), but hormonal disorders that have led to pathologic and histological changes in the tissues of GZ continue to exist for a long time and can lead to repeated nodal formations. In group І, 25% of patients within 2 years performed repeated sectoral resections on recurrence of nodule formation.

In group І, 25% of patients within 2 years performed repeated sectoral resections on recurrence of nodule formation. The use of Mastodynon® in standard doses (group II) for postoperative rehabilitation contributes to a significant improvement in hormonal homeostasis (normalization of prolactin, estradiol and progesterone levels), a 24.7 mm decrease in the degree of cyclic mastodynia according to the visual analog scale (VAS), and the improvement of ultrasound scan Pictures of GZ in 75% of patients. The most pronounced effect of this rehabilitation approach after the surgical treatment phase was noted for the use of Mastodynone in doble doses (2 tablets or 60 drops 2 times a day) in Group III. In these patients, the degree of reduction of cyclic mastodynia was 30 mm for VAS and positive changes in the tissues of GH were noted in 85% of patients. However, the highest incidence of adverse events was also noted in Group III, although they were temporary in nature and did not require withdrawal or dose reduction.

Conclusion. Despite the presence of short-term side effects and rapid rebounding in the double-dose Mastodynon® group, our study showed better results than standard doses, faster and more stable therapeutic effect. Taking into account the results obtained, it can be argued that the use of high doses of Mastodynon® may be recommended to patients for the treatment of mastopathy.

For a more complete study of such an important aspect as the tolerability of high doses of Mastodynon®, it is advisable to conduct more extensive studies, taking into account the dosage form and the use of other drugs.

Key words: mastopathy, postoperative rehabilitation, Mastodynon®, mastodynia.

References

1. Smolanka II, Liashenko AO. 2007. Fibrozno-kistozna mastopatiia. Zhinochyi likar 1:16.

2. Zaitsev VF, Nikolaienko TA, Suhak SV. 1999. Taktyka khirurha pry vuzlovykh utvorenniakh molochnykh zaloz. Aktualni problemy klinichnoi medytsyny. Mn.:35–36.

3. Vyisotskaya IV, Letyagin VP, Kim EA. 2006. Disgormonalnyie displazii molochnyih zhelez. Mammologiya 2:9–12.

4. Andreeva EN, Ledneva EV. 2002. Osnovnyie aspektyi etiologii i patogeneza fibrozno-kistoznoy bolezni molochnoy zhelezyi. Akusherstvo i ginekologiya 6:7–9.

5. Tagieva TT, Volobuev AI. 2002. Primenenie Mastodinona u zhenschin s fibrozno-kistoznoy mastopatiey. Zdorov’ya UkraYini 5.

6. Wuttke W, Jarry H, Christoffe V, Spengler B and Seidlovб-Wuttke D. 2003. Chaste tree (Vitex agnus-castus) – Pharmacology and clinical indications. Phytomedicine 10: 348–357. https://doi.org/10.1078/094471103322004866; PMid:12809367